Literature DB >> 9749570

Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration?

D P Perl1, C W Olanow, D Calne.   

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are generally considered to be separate and distinct disease entities. However, a considerable amount of evidence demonstrates that these disorders share common clinical and neuropathologic features and that overlap between the two conditions is extensive. For example, a significant percentage of AD patients exhibit extrapyramidal features, and many PD patients develop dementia. Similarly, at autopsy many AD patients not only exhibit the neuropathologic features of that disorder but also exhibit nigral pathology, including Lewy bodies. The vast majority of demented PD patients show widespread neurofibrillary tangles and senile plaques as well as Lewy body formation and nigral degeneration. The extent of such overlap is far greater than one would anticipate by chance alone. We argue that such overlap reflects a common pathogenic mechanism for the neurodegeneration encountered within specific vulnerable neuronal populations. Furthermore, we suggest that the current nosologic approach, which attempts to separate AD from PD, fails to properly deal with the issue of overlap and that a new classification of the neurodegenerative disorders should be considered.

Entities:  

Mesh:

Year:  1998        PMID: 9749570     DOI: 10.1002/ana.410440705

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 2.  Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?

Authors:  Hutan Ashrafian; Leanne Harling; Ara Darzi; Thanos Athanasiou
Journal:  Metab Brain Dis       Date:  2013-05-08       Impact factor: 3.584

3.  Exploratory data from complete genomes of familial alzheimer disease age-at-onset outliers.

Authors:  Matthew A Lalli; Gloria Garcia; Lucia Madrigal; Mauricio Arcos-Burgos; Mary Luz Arcila; Kenneth S Kosik; Francisco Lopera
Journal:  Hum Mutat       Date:  2012-08-10       Impact factor: 4.878

4.  APOE and LRPAP1 gene polymorphism and risk of Parkinson's disease.

Authors:  Neeraj Kumar Singh; Basu Dev Banerjee; Kiran Bala; Aldrin Anthony Dung Dung; Neelam Chhillar
Journal:  Neurol Sci       Date:  2014-02-07       Impact factor: 3.307

Review 5.  Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease).

Authors:  Clovis Foguem; Patrick Manckoundia
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-08       Impact factor: 5.081

Review 6.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

7.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

8.  A Case of Biopsy-proven Early-onset Alzheimer's Disease with Hemiparkinsonism.

Authors:  Eun Jung Choi; Hyun Bang; Joo Hyuk Im; Sun Joo Chung; Jae-Hong Lee
Journal:  J Clin Neurol       Date:  2005-04-30       Impact factor: 3.077

Review 9.  Chasing genes in Alzheimer's and Parkinson's disease.

Authors:  Aida M Bertoli-Avella; Ben A Oostra; Peter Heutink
Journal:  Hum Genet       Date:  2004-03-04       Impact factor: 4.132

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.